Search results for "DEEP VENOUS THROMBOSIS"

showing 6 items of 6 documents

Leukocyte Rheology Before and After Chemotactic Activation in some Venous Diseases

1999

Abstract Objective: to evaluate leukocyte rheology, polymorphonuclear leukocyte (PMN) membrane fluidity and cytosolic Ca2+ concentration in subjects with post-phlebitic leg syndrome (PPS) and acute deep-venous leg thrombosis (DVT). Subjects: twenty-two subjects with leg PPS and 14 subjects with leg DVT. Methods: we evaluated the leukocyte filtration (unfractionated, mononuclear cells (MN) and PMN), the PMN membrane fluidity and the PMN cytosolic Ca2+ concentration. Subsequently, we evaluated the same PMN variables after in vitro chemotactic activation with 4-phorbol 12-myristate 13-acetate (PMA) and N -formyl-methionyl-leucyl-phenylalanine (fMLP). Results: at baseline we observed a signific…

Malemedicine.medical_specialtyTime FactorsMembrane FluidityNeutrophilsPostphlebitic SyndromeIn Vitro TechniquesNeutrophil activation.Peripheral blood mononuclear cellMonocytesNeutrophil ActivationCytosolWhite blood cell filtrationInternal medicinemedicineMembrane fluidityHumansMedicine(all)Venous ThrombosisPolymorphonuclear leukocytebusiness.industrySignificant differenceChemotaxishemic and immune systemsChronic venous insufficiencyMiddle Agedmedicine.diseaseThrombosisIn vitroChemotaxis LeukocyteCytosolEndocrinologyHemorheologyImmunologyDeep venous thrombosisCalciumFemaleSurgeryCardiology and Cardiovascular MedicinebusinessEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the Emergency Department…

2021

Background and importance A higher incidence of venous thromboembolism [both pulmonary embolism and deep vein thrombosis (DVT)] in patients with coronavirus disease 2019 (COVID-19) has been described. But little is known about the true frequency of DVT in patients who attend emergency department (ED) and are diagnosed with COVID-19. Objective We investigated the incidence, risk factors, clinical characteristics and outcomes of DVT in patients with COVID-19 attending the ED before hospitalization. Methods We retrospectively reviewed all COVID patients diagnosed with DVT in 62 Spanish EDs (20% of Spanish EDs, case group) during the first 2 months of the COVID-19 outbreak. We compared DVT-COVI…

MaleDeep veinComorbidity030204 cardiovascular system & hematologyChest pain0302 clinical medicineRisk Factorsrisk factorsclinical characteristicsIncidenceIncidence (epidemiology)Age FactorsVenous ThromboembolismMiddle AgedPulmonary embolismVenous thrombosismedicine.anatomical_structureEmergency MedicineoutcomeFemalemedicine.symptomEmergency Service Hospitalsevere acute respiratory syndrome coronavirus 2Adultmedicine.medical_specialtyRisk Assessment03 medical and health sciencescoronavirus disease 2019Internal medicineThromboembolismmedicineHumanscardiovascular diseasesTromboembolismeAgedRetrospective Studiesdeep venous thrombosisbusiness.industryCOVID-19030208 emergency & critical care medicineRetrospective cohort studyOriginal ArticlesEmergency departmentOdds ratiomedicine.diseaseSpainCase-Control StudiesincidencePulmonary Embolismbusiness
researchProduct

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Deep venous thrombosis: Behaviour of the polymorphonuclear leukocyte integrin pattern at baseline and after in vitro activation

2005

In a group of 18 subjects with acute deep venous thrombosis (DVT), evidenced by clinical examination and echo-color-Doppler, we examined the phenotypical expression of the polymorphonuclear leukocyte (PMN) beta2-integrins (CD11a, CD11b, CD11c, CD18), obtained by using a flow cytofluorimeter. The evaluation was performed before and after in vitro activation (prolonged for 5 and 15 minutes) with 4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP). In DVT subjects, at baseline, the phenotypical expression of CD11b was decreased and that of CD11c was increased when compared with normal controls; no difference was found in CD11a and CD18 expression. In norm…

AdultMaleVenous ThrombosisIntegrinsSettore MED/09 - Medicina InternaCD11 AntigensNeutrophilsDeep venous thrombosis; polymorphonuclear leukocyte integrins; polymorphonuclear leukocyte activationMiddle AgedFlow CytometryNeutrophil ActivationDeep venous thrombosis polymorphonuclear leukocyte integrins polymorphonuclear leukocyte activationpolymorphonuclear leukocyte integrinsGene Expression RegulationCD18 AntigensCase-Control StudiesDeep venous thrombosisHumansTetradecanoylphorbol AcetateFemalepolymorphonuclear leukocyte activationAged
researchProduct

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis.

2019

Multiple studies have shown that in approximately half of individuals with pulmonary embolism (PE), the deep venous thrombosis (DVT) is not evident at the moment of PE diagnosis. The underlying factors and the origin of PE in these patients are not completely understood: missed DVT, embolization of DVT in its entirety, or de-novo PE being possible explanations. The aim of this study was to evaluate the differences in PE patient with or without co-existing DVT. Sixty-three consecutive PE patients were included. Whole leg bilateral Doppler compression ultrasound was performed to all patients. The PE location and extension, C-reactive protein, platelet count, hemostatic markers FV, FVIII, FXII…

AdultMalemedicine.medical_specialtyVEIN THROMBOSISmedicine.medical_treatment030204 cardiovascular system & hematologyFibrinogenPulmonary function testing03 medical and health sciencesTHROMBOEMBOLISM0302 clinical medicineInternal medicineSCOREmedicineFactor V LeidenFACTOR-V-LEIDENHumanscardiovascular diseasesEmbolizationProspective Studiescoagulationhemostatic markersProspective cohort studydeep venous thrombosisAgedRISKVenous ThrombosisHemostasisLegbusiness.industryUltrasonography DopplerHematologyGeneral MedicineNITRIC-OXIDE MEASUREMENTSMiddle Agedmedicine.disease3. Good healthPulmonary embolismVenous thrombosis3121 General medicine internal medicine and other clinical medicineHemostasisisolated pulmonary embolismCardiologyFemalebusinessPulmonary Embolism030215 immunologymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct